RKTO Overview

Rocket One Inc., formerly Hoth Therapeutics, Inc., is focused on developing and commercializing infrastructure for the orbital economy, including nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The Company holds exclusive rights to certain technologies, including a nanomagnetic matrix multiplier architecture intended as a hardware accelerator for machine learning and AI workloads, and related magnetic memory technology with potential applications in radiation-tolerant computing for defense and space systems. The Company is also positioned to pursue opportunities in nano-launch systems and nanosatellite deployment. The Company's biotechnology pipeline includes HT-001, HT-KIT, HT-ALZ, and GDNF-based metabolic program.

Wall Street analysts forecast RKTO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RKTO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Rocket One Inc revenue for the last quarter amounts to -2.65M USD, decreased -23.81

Rocket One Inc. EPS for the last quarter amounts to USD, decreased

Rocket One Inc (RKTO) has 2 emplpoyees as of June 12 2026.

Today RKTO has the market capitalization of 33.04M USD.